Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 7/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259587 | 0.80 | BTK (0.43) | GAAL3MBTL1 | |
| SCHEMBL13387564 | 0.77 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL4719490 | 0.77 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL27688525 | 0.75 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL30241859 | 0.73 | TSHR (0.53) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL16526220 | 0.72 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL25326797 | 0.72 | GAA (0.49) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL12510922 | 0.72 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL8259162 | 0.72 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL4282204 | 0.72 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | GAA 4203/4885MAPK1 1/4885HTT 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.